Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies
Abstract Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future managem...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Biological Procedures Online |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12575-025-00287-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388121040355328 |
|---|---|
| author | Xiaoyu Yang Bin Luo Jianhui Tian Yanhong Wang Xinyi Lu Jian Ni Yun Yang Lei Jiang Shengxiang Ren |
| author_facet | Xiaoyu Yang Bin Luo Jianhui Tian Yanhong Wang Xinyi Lu Jian Ni Yun Yang Lei Jiang Shengxiang Ren |
| author_sort | Xiaoyu Yang |
| collection | DOAJ |
| description | Abstract Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future management of lung cancer. However, due to immune resistance, immunotherapy remains highly effective in only a subset of patients, while many others either do not respond initially or develop resistance over time. Moreover, immune-related adverse events induced by immunotherapy, further complicate treatment outcomes and prognosis. Immune-related biomarkers and ImmuneScores have driven the development of personalized immunotherapy strategies for lung cancer, and they can aid in predicting immune resistance, and forecasting immune-related adverse events (irAEs). This review summarizes the prognosis value of immune-related biomarkers and ImmuneScores in immunotherapy and combination therapies for lung cancer. The aim is to provide a foundation for personalized treatment and management of lung cancer, while offering guidance for future research directions in immunotherapy. |
| format | Article |
| id | doaj-art-16b7a468471d4dc5b97722b5b0cc239d |
| institution | Kabale University |
| issn | 1480-9222 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Biological Procedures Online |
| spelling | doaj-art-16b7a468471d4dc5b97722b5b0cc239d2025-08-20T03:42:23ZengBMCBiological Procedures Online1480-92222025-07-0127111810.1186/s12575-025-00287-0Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategiesXiaoyu Yang0Bin Luo1Jianhui Tian2Yanhong Wang3Xinyi Lu4Jian Ni5Yun Yang6Lei Jiang7Shengxiang Ren8Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineDepartment of Lung Cancer, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineDepartment of Lung Cancer, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityDepartment of Lung Cancer, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityAbstract Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future management of lung cancer. However, due to immune resistance, immunotherapy remains highly effective in only a subset of patients, while many others either do not respond initially or develop resistance over time. Moreover, immune-related adverse events induced by immunotherapy, further complicate treatment outcomes and prognosis. Immune-related biomarkers and ImmuneScores have driven the development of personalized immunotherapy strategies for lung cancer, and they can aid in predicting immune resistance, and forecasting immune-related adverse events (irAEs). This review summarizes the prognosis value of immune-related biomarkers and ImmuneScores in immunotherapy and combination therapies for lung cancer. The aim is to provide a foundation for personalized treatment and management of lung cancer, while offering guidance for future research directions in immunotherapy.https://doi.org/10.1186/s12575-025-00287-0Lung cancerImmunotherapyBiomarkersImmuneScoresCombination TherapyPrediction |
| spellingShingle | Xiaoyu Yang Bin Luo Jianhui Tian Yanhong Wang Xinyi Lu Jian Ni Yun Yang Lei Jiang Shengxiang Ren Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies Biological Procedures Online Lung cancer Immunotherapy Biomarkers ImmuneScores Combination Therapy Prediction |
| title | Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies |
| title_full | Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies |
| title_fullStr | Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies |
| title_full_unstemmed | Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies |
| title_short | Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies |
| title_sort | biomarkers and immunescores in lung cancer predictive insights for immunotherapy and combination treatment strategies |
| topic | Lung cancer Immunotherapy Biomarkers ImmuneScores Combination Therapy Prediction |
| url | https://doi.org/10.1186/s12575-025-00287-0 |
| work_keys_str_mv | AT xiaoyuyang biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT binluo biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT jianhuitian biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT yanhongwang biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT xinyilu biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT jianni biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT yunyang biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT leijiang biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies AT shengxiangren biomarkersandimmunescoresinlungcancerpredictiveinsightsforimmunotherapyandcombinationtreatmentstrategies |